PTPN11 - Wiki-Pi

Search Results for: PTPN11

Can't find the interaction you're looking for? Try the advanced search

174 interactions involving PTPN11 - protein tyrosine phosphatase non-receptor type 11 found:

Sort by: Symbol Number of Pathways Number of Drugs Number of Diseases

Symbol	Description	Pathways Hide	Drugs Hide	Diseases Hide
EPHA1	EPH receptor A1	EPH-Ephrin signaling EPH-Ephrin signaling POU5F1 (OCT4), SOX2, NANOG activate genes related to proliferation EPHA-mediated growth cone collapse EPHA-mediated growth cone collapse EPH-ephrin mediated repulsion of cells EPH-ephrin mediated repulsion of cells	Fostamatinib
EPHA2	EPH receptor A2	EPH-Ephrin signaling EPH-Ephrin signaling EPHA-mediated growth cone collapse EPHA-mediated growth cone collapse EPH-ephrin mediated repulsion of cells EPH-ephrin mediated repulsion of cells RAC1 GTPase cycle RAC2 GTPase cycle RHOG GTPase cycle RHOU GTPase cycle RAC3 GTPase cycle RHOV GTPase cycle RND3 GTPase cycle RND2 GTPase cycle RND1 GTPase cycle	Dasatinib Phosphoaminophosphonic Acid-Adenylate Ester Regorafenib Fostamatinib
EPOR	erythropoietin receptor	Signaling by Erythropoietin Signaling by Erythropoietin Erythropoietin activates Phosphoinositide-3-kinase (PI3K) Erythropoietin activates Phosphoinositide-3-kinase (PI3K) Erythropoietin activates Phospholipase C gamma (PLCG) Erythropoietin activates STAT5 Erythropoietin activates RAS Erythropoietin activates RAS	Darbepoetin alfa Erythropoietin Dibromotyrosine Peginesatide Methoxy polyethylene glycol-epoetin beta	Congenital polycythemia; Familial erythrocytosis (ECYT)
ERBB2	erb-b2 receptor tyrosine kinase 2	Signaling by ERBB2 SHC1 events in ERBB2 signaling SHC1 events in ERBB2 signaling PLCG1 events in ERBB2 signaling PIP3 activates AKT signaling GRB7 events in ERBB2 signaling Downregulation of ERBB2:ERBB3 signaling GRB2 events in ERBB2 signaling GRB2 events in ERBB2 signaling PI3K events in ERBB2 signaling Constitutive Signaling by Aberrant PI3K in Cancer Sema4D induced cell migration and growth-cone collapse RAF/MAP kinase cascade ERBB2 Regulates Cell Motility PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling ERBB2 Activates PTK6 Signaling Downregulation of ERBB2 signaling TFAP2 (AP-2) family regulates transcription of growth factors and their receptors Constitutive Signaling by Overexpressed ERBB2 Drug-mediated inhibition of ERBB2 signaling Signaling by ERBB2 KD Mutants Resistance of ERBB2 KD mutants to trastuzumab Resistance of ERBB2 KD mutants to sapitinib Resistance of ERBB2 KD mutants to tesevatinib Resistance of ERBB2 KD mutants to neratinib Resistance of ERBB2 KD mutants to osimertinib Resistance of ERBB2 KD mutants to afatinib Resistance of ERBB2 KD mutants to AEE788 Resistance of ERBB2 KD mutants to lapatinib Signaling by ERBB2 ECD mutants Signaling by ERBB2 TMD/JMD mutants Drug resistance in ERBB2 TMD/JMD mutants Developmental Lineage of Mammary Gland Luminal Epithelial Cells Developmental Lineage of Mammary Gland Myoepithelial Cells Developmental Lineage of Mammary Stem Cells	Trastuzumab Lapatinib IGN311 Trastuzumab emtansine Varlitinib AV-412 Pertuzumab Afatinib Tucatinib Tesevatinib Fostamatinib Brigatinib Margetuximab Zanubrutinib	Breast cancer Cervical cancer Cholangiocarcinoma Pancreatic cancer Gastric cancer Ovarian cancer Choriocarcinoma Endometrial Cancer Bladder cancer
ERBB3	erb-b2 receptor tyrosine kinase 3		Tucatinib	Type I diabetes mellitus Lethal congenital contractural syndrome (LCCS)
ERBB4	erb-b2 receptor tyrosine kinase 4		Afatinib Fostamatinib Brigatinib Zanubrutinib
FCGR1BP	Fc gamma receptor Ib, pseudogene
FCGR2B	Fc gamma receptor IIb	Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell	Etanercept Human immunoglobulin G Abciximab Tositumomab Alemtuzumab Antithymocyte immunoglobulin (rabbit) Palivizumab Daclizumab Bevacizumab Sarilumab	Systemic lupus erythematosus
FCRL3	Fc receptor like 3
FGFR2	fibroblast growth factor receptor 2	Signaling by FGFR2 amplification mutants Activated point mutants of FGFR2 Signaling by FGFR2 in disease Signaling by FGFR2 IIIa TM Signaling by FGFR2 fusions	Palifermin Heparin Sucrosofate 3-[4-(1-formylpiperazin-4-yl)-benzylidenyl]-2-indolinone 4-[4-(1-Amino-1-Methylethyl)Phenyl]-5-Chloro-N-[4-(2-Morpholin-4-Ylethyl)Phenyl]Pyrimidin-2-Amine Regorafenib Ponatinib Lenvatinib Nintedanib Foreskin fibroblast (neonatal) Foreskin keratinocyte (neonatal) Infigratinib Fostamatinib Erdafitinib Pemigatinib Futibatinib Selpercatinib Pralsetinib	Lacrimo-auriculo-dento-digital syndrome (LADD); Levy-Hollister syndrome Gastric cancer Craniosynostosis, including: Pfeiffer syndrome; Apert syndrome; Crouzon syndrome; Jackson-Weiss syndrome; Beare-Stevenson syndrome; Muenke craniosynostosis; Saethre-Chotzen syndrome; Craniosynostosis Boston type; Antley-Bixler syndrome; Carpenter syndrome; Craniofrontonasal dysplasia; Noonan syndrome; Baller-Gerold syndrome
FGFR4	fibroblast growth factor receptor 4	PI3K Cascade PIP3 activates AKT signaling betaKlotho-mediated ligand binding FGFR4 mutant receptor activation FGFR4 ligand binding and activation Constitutive Signaling by Aberrant PI3K in Cancer Phospholipase C-mediated cascade; FGFR4 FRS-mediated FGFR4 signaling SHC-mediated cascade:FGFR4 PI-3K cascade:FGFR4 Negative regulation of FGFR4 signaling Signaling by FGFR4 in disease RAF/MAP kinase cascade PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling	Heparin Ponatinib Lenvatinib Infigratinib Erdafitinib Pemigatinib Futibatinib
FLT1	fms related receptor tyrosine kinase 1	Neurophilin interactions with VEGF and VEGFR VEGF binds to VEGFR leading to receptor dimerization	Sorafenib Sunitinib Vatalanib TG-100801 OSI-930 Denibulin Linifanib IMC-1C11 Pazopanib Axitinib N-(4-chlorophenyl)-2-[(pyridin-4-ylmethyl)amino]benzamide Regorafenib Lenvatinib Nintedanib Polaprezinc Foreskin fibroblast (neonatal) Tivozanib Fostamatinib Selpercatinib
FLT3	fms related receptor tyrosine kinase 3	PI3K Cascade PIP3 activates AKT signaling Constitutive Signaling by Aberrant PI3K in Cancer RAF/MAP kinase cascade PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling FLT3 Signaling FLT3 Signaling STAT5 Activation FLT3 mutants bind TKIs STAT5 activation downstream of FLT3 ITD mutants KW2449-resistant FLT3 mutants semaxanib-resistant FLT3 mutants crenolanib-resistant FLT3 mutants gilteritinib-resistant FLT3 mutants lestaurtinib-resistant FLT3 mutants midostaurin-resistant FLT3 mutants pexidartinib-resistant FLT3 mutants ponatinib-resistant FLT3 mutants quizartinib-resistant FLT3 mutants sorafenib-resistant FLT3 mutants sunitinib-resistant FLT3 mutants tandutinib-resistant FLT3 mutants linifanib-resistant FLT3 mutants tamatinib-resistant FLT3 mutants Signaling by FLT3 ITD and TKD mutants Signaling by FLT3 ITD and TKD mutants Negative regulation of FLT3 FLT3 signaling through SRC family kinases FLT3 signaling through SRC family kinases FLT3 signaling by CBL mutants	Sorafenib Sunitinib XL999 Tandutinib Linifanib Lestaurtinib Midostaurin Ponatinib Nintedanib Pacritinib Tivozanib Fostamatinib Gilteritinib Brigatinib Fedratinib Amuvatinib Quizartinib Pexidartinib Pralsetinib	Acute myeloid leukemia (AML)
FLT4	fms related receptor tyrosine kinase 4	VEGF binds to VEGFR leading to receptor dimerization NOTCH4 Intracellular Domain Regulates Transcription High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells	Sorafenib Sunitinib Vatalanib TG-100801 Denibulin Linifanib IMC-1C11 Pazopanib Axitinib Regorafenib Lenvatinib Nintedanib Tivozanib Fostamatinib Selpercatinib	Lymphedemas, including: Lymphedema, hereditary I; Lymphedema-distichiasis syndrome (LD); Hypotrichosis-lymphedema-telangiectasia syndrome (HLTS)
FRS2	fibroblast growth factor receptor substrate 2	PI3K Cascade PIP3 activates AKT signaling Frs2-mediated activation Frs2-mediated activation Signaling by ALK Constitutive Signaling by Aberrant PI3K in Cancer PI-3K cascade:FGFR1 FRS-mediated FGFR1 signaling PI-3K cascade:FGFR2 FRS-mediated FGFR2 signaling FRS-mediated FGFR3 signaling PI-3K cascade:FGFR3 FRS-mediated FGFR4 signaling PI-3K cascade:FGFR4 Negative regulation of FGFR1 signaling Negative regulation of FGFR2 signaling Negative regulation of FGFR3 signaling Negative regulation of FGFR4 signaling Signaling by FGFR2 in disease Signaling by FGFR4 in disease Signaling by FGFR1 in disease Signaling by FGFR3 in disease RAF/MAP kinase cascade PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling RET signaling Activated NTRK2 signals through FRS2 and FRS3 Activated NTRK2 signals through FRS2 and FRS3 RND2 GTPase cycle RND1 GTPase cycle Signaling by ALK fusions and activated point mutants
FRS3	fibroblast growth factor receptor substrate 3	FRS-mediated FGFR1 signaling FRS-mediated FGFR2 signaling FRS-mediated FGFR3 signaling FRS-mediated FGFR4 signaling RAF/MAP kinase cascade Activated NTRK2 signals through FRS2 and FRS3 RND2 GTPase cycle RND1 GTPase cycle Signaling by ALK fusions and activated point mutants
FYN	FYN proto-oncogene, Src family tyrosine kinase	GPVI-mediated activation cascade Signaling by ERBB2 PIP3 activates AKT signaling Signaling by SCF-KIT Signaling by SCF-KIT Regulation of KIT signaling Nef and signal transduction Cell surface interactions at the vascular wall FCGR activation PECAM1 interactions Constitutive Signaling by Aberrant PI3K in Cancer DAP12 signaling DAP12 signaling EPH-Ephrin signaling Role of LAT2/NTAL/LAB on calcium mobilization Nephrin family interactions Nephrin family interactions NCAM signaling for neurite out-growth NCAM signaling for neurite out-growth Co-stimulation by CD28 CD28 dependent PI3K/Akt signaling CD28 dependent Vav1 pathway Co-inhibition by CTLA4 EPHB-mediated forward signaling EPHB-mediated forward signaling EPHA-mediated growth cone collapse EPHA-mediated growth cone collapse Ephrin signaling Ephrin signaling EPH-ephrin mediated repulsion of cells Sema3A PAK dependent Axon repulsion SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion CRMPs in Sema3A signaling CRMPs in Sema3A signaling VEGFA-VEGFR2 Pathway Dectin-2 family CD209 (DC-SIGN) signaling RAF/MAP kinase cascade PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling Platelet Adhesion to exposed collagen Reelin signalling pathway Regulation of signaling by CBL Regulation of signaling by CBL FCGR3A-mediated IL10 synthesis FCGR3A-mediated phagocytosis Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants Signaling by CSF1 (M-CSF) in myeloid cells FLT3 signaling through SRC family kinases Antigen activates B Cell Receptor (BCR) leading to generation of second messengers High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells	Dasatinib Triglyme Fostamatinib Zotiraciclib
GAB1	GRB2 associated binding protein 1	PI3K Cascade Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants PIP3 activates AKT signaling GAB1 signalosome PI3K events in ERBB2 signaling Constitutive Signaling by Aberrant PI3K in Cancer Constitutive Signaling by EGFRvIII PI-3K cascade:FGFR1 PI-3K cascade:FGFR2 PI-3K cascade:FGFR3 PI-3K cascade:FGFR4 Signaling by FGFR2 in disease Signaling by FGFR4 in disease Signaling by FGFR1 in disease Signaling by FGFR3 in disease PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling MET activates PI3K/AKT signaling RET signaling MET activates PTPN11 MET activates RAP1 and RAC1 MET receptor recycling Erythropoietin activates Phosphoinositide-3-kinase (PI3K) Activated NTRK2 signals through PI3K Signaling by ERBB2 KD Mutants Signaling by ERBB2 ECD mutants
GAB2	GRB2 associated binding protein 2	PI3K Cascade PIP3 activates AKT signaling Signaling by SCF-KIT Signaling by cytosolic FGFR1 fusion mutants Constitutive Signaling by Aberrant PI3K in Cancer Role of LAT2/NTAL/LAB on calcium mobilization Role of LAT2/NTAL/LAB on calcium mobilization PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling RET signaling Interleukin-15 signaling Interleukin receptor SHC signaling FLT3 Signaling FLT3 Signaling STAT5 Activation Signaling by CSF3 (G-CSF) Signaling by CSF3 (G-CSF) Signaling by CSF1 (M-CSF) in myeloid cells STAT5 activation downstream of FLT3 ITD mutants Signaling by FLT3 fusion proteins Signaling by FLT3 fusion proteins Signaling by FLT3 ITD and TKD mutants Signaling by FLT3 ITD and TKD mutants
GAB3	GRB2 associated binding protein 3	Signaling by CSF1 (M-CSF) in myeloid cells

Page 3 out of 9 pages